KALY Patented Cannabis Extract COPD Treatment Research Validates Pharmaceutical Potential
Source: InvestorsHub NewsWire
New York, NY -- March 25, 2019 -- InvestorsHub NewsWire -- via NextBigtTcker.com
?
Kali-Extracts, Inc. (USOTC: KALY) last Friday, March 22nd, published the research results from the recent trial of its pilot treatment for Chronic Obstructive Pulmonary Disease (COPD) in primates using an extract derived from KALY's patented cannabis extraction process. The independent research publication reported that the KALY compound improved respiration in infected primates further validating previous in vitro studies of KALY’s cannabis compound. The research publication recommended next stage trials. The research publication elevates KALY from just having a patented extraction process to actually having the potential of being able to produce a cannabis extract pharmaceutical product.
KALY Potential PPS Run From $0.01 to $0.10
KALY has the potential to run from its $0.01 PPS level to $0.10 in the near term. Shortly after the 2018 Q4 acquisition of the patented cannabis extraction process, the company PPS shot from sub-penny land to almost $0.04 on volume that put it in the top 20 most actively traded stocks on the OTC Market. The PPS retraced back to $0.01 and has been holding that price with a healthy trading volume. With the research publication now validating KALY as a serious pharmaceutical contender, the PPS is positioned to shoot past the recent $0.04 highs to a level putting it on par with some of the other penny cannabis stock contenders such as PotNetworks Holdings, Inc. (USOTC: POTN) and Medical Marijuana, Inc. (USOTC: MJNA). A $0.10 PPS is a reasonable milestone following the company filing its upcoming annual reported expected to include the company posting its first revenue derived from its cannabis extraction process.
KALY is providing CBD extracts for over $1 million worth of CBD infused water produced by Puration, Inc. (USOTC: PURA), and KALY has also introduced its own CBD infused gum. When the annual report is published in April, the first sales will be officially on the books and likely catapult the KALY PPS up to the $0.10 range were it justifiably should be. Between now and the filing of the annual report, the KALY PPS stands to return to its previous $0.04 high on anticipated news regarding its cannabis pharmaceutical developments and wellness product sales.
Following the acquisition of the patented cannabis extraction process late last year and the corresponding jump in price and trading volume, the OTC Markets flagged the company in response to the jump in activity. The company has responded by updating all its OTC Markets required reports. Management is likely to mitigate the OTC Market’s concerns sooner or later and see the flag removed which will likely be yet another impetus fueling a KALY PPS run. It could be a good time to accumulate KALY now under $0.04 before the positing of the company’s annual report or the removal of the OTC Markets flag.
Management engaged Goldman Small Cap Research to conduct analyst coverage of the company and file an initial analyst report: KALY Research Report
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.
Source: www.nextbigticker.com
AI
